fibrinolysin because of this error. The qualitative fibrinolysin test will also give false negative results when the enzyme is present in excess but is not strong enough to cause complete lysis of the clot. In these cases, Macfarlane (1937) has recommended using dilute plasma to bring out the fibrinolytic activity. While this method is an improvement over the blood-clot incubation technique, it may still give false positive and false negative results. Furthermore, it gives only a qualitative measure of the defect. Bidwell (1953) and Bidwell and Macfarlane (1951) have attempted to convert Macfarlane's qualitative technique to a quantitative one, and the method now presented is essentially a modification of this method. The quantitative method to be described is useful for any clinical laboratory that is able to do fibrinogen determinations. It has been applied to the routine investigation of coagulation problems, and in addition has been used to study the characteristics of the fibrinolysin in the plasma of a patient with carcinoma of the prostate.
Methods
Defibrinogenation of Plasna.I-This was carried out in one of two ways: (1) The plasma was heated for three minutes at 560 C. and was centrifuged for five minutes at 1,000 r.p.m. Then the supematant defibrinogenated plasma was separated. (2) One hundred units of thrombin were added to each millilitre of plasma to be defibrinogenated. The clot which formed was squeezed out with a glass rod and removed, leaving behind the defibrinogenated material.
Activation of Pro-fibrinolysin.-Two methods were used. The chloroform technique (Tagnon, 1942) for activation of pro-fibrinolysin consisted of adding 0.1 ml. of chloroform plus 0.04 ml. of 0.5 M CaCl2 to each millilitre of plasma. The mixture was incubated at 370 C. for 30 minutes, then centrifuged. The chloroform layer was removed. The residual serum was kept uncovered overnight in the refrigerator, and was ready for use the next morning. The varidase method (Loomis, 1955) consisted of adding 0.1 ml. of varidase (10,000 units of streptokinase and 2,500 units of streptodomase) to each millilitre of plasma. The mixture was incubated for one hour at 370 C.
Purification of Commercial Fibrinogen.-Bovine fibrinogen (Armour) and Cohn's fraction I (obtained from the American Red Cross) prepared from human plasma were used as the starting material. The purification was carried out by Laki's technique (1951) .
Fibrin Detenninahion.-Fibrin levels were measured by tyrosine determination using Folin-Ciocalteu (1927) phenol reagent as described by Quick (1951) . One millilitre of plasma was diluted to 25 ml. with saline or distilled water plus 100 units of thrombin. The resultant clot was incubated at 370 C. for various periods of time as noted below. In the routine fibrin determination, the clot was removed from the 25-ml. mixture by winding around a glass stirring rod. This method was not adequate for fibrinolysin studies, since the clots, especially after long incubation, were extremely fragile. Consequently, fibrin was separated by filtration through a glass wool filter. (Stefanini, 1952) .
Procedure. -The technique recommended for measurement of fibrinolysin in clinical laboratories is as follows:
1. Heat fresh normal plasma and test plasma to 56' C. for three minutes. Cool. Centrifuge. Save supernatants (defibrinogenated plasma).
2. Add I ml. of normal plasma to each of four tubes labelled A, B, C, and D.
3. To tubes A and B add 1 ml. of defibrinogenated normal plasma. To tubes C and D add 1 ml. of defibrinogenated test plasma.
4. Bring total volume in each tube to 24 ml. with saline. Place all four tubes in incubator at 370 C.
5. Add 1 ml. of thrombin (100 units per ml.) to each tube.
6. After 15 minutes' incubation, take tubes A and C from water bath. Filter through glass wool. Wash glass wool-clot mixture repeatedly with distilled water. Squeeze out excess moisture.
7. Do tyrosine determinations on both clots. 8. After 24 hours of incubation, carry out steps 6 and 7 on tubes B and D.
9. Final results are expressed in terms of percentage loss of fibrin.
Results Experiment 1.-In this experiment,-20 tubes were each filled with 24 ml. of saline. The tubes were divided into two sets of 10 each. To each of the 10 tubes in set 1, 1 ml. of normal plasma was added. One millilitre of fibrinolytic plasma was added to each of the 10 tubes in set 2. All 20 tubes were placed in an incubator at 37°C. and thrombin was added. At intervals as noted in Fig. 1 , two tubes-one from each set-were withdrawn from the incubator and fibrin levels were determined. The fibrin levels, when plotted against time, gave an S-shaped curve both in the normal subject and in the patient with active fibrinolysin. Often fibrinolytic activity is also fibrinogenolytic. In the case of the patient under discussion, however, the fibrinolysin was sufficiently mild so that his plasma fibrinogen level was only slightly lower than the normal. If his starting fibrinogen level (at time 0) were lower, this comparison between normal and patient could not be carried out as readily (Table I) . 
Discussion
In experiment 1 an example is presented of fibrinolytic activity in the plasma of a normal subject as compared with the activity in the plasma of a patient with carcinoma of the prostate. The result for the normal subject was similar to that obtained in the 23 normal controls similarly tested ( Fig. 1 and Table V) . Using a qualitative method. Truelove (1953) was also able to demonstrate fibrinolysin in most normal plasmas on 24-hour incubation. Thus, the mere demonstration of fibrinolysis is without pathological significance. The degree of lysis is the important factor. In Fig. 1 (Tables II and III ). In Table   II (1951) in two important points: (1) These workers did not defibrinogenate their test plasma and substitute normal plasma as substrate, and (2) they removed the clot after 24 hours' incubation by means of a glass rod. This latter method has been found to be extremely difficult to use, especially in cases with mild fibrinolysis. Consequently, filtration through glass wool is recommended.
It should be stressed that the plasma used in step 1 should not be kept at room temperature or at 370 C. for too long a period of time before testing, since fibrinolysin is somewhat labile (Jacobsson, 1955; Truelove, 1953) and will decrease in activity on prolonged standing.
A possible criticism of this method may be raised on the grounds that heat defibrinogenation may destroy some of the fibrinolysin. However, Fig. 3 shows that there is no significant difference when defibrinogenation is carried out by heat or by thrombin. Furthermore, the fact that the addition of thrombin does not cause a greater amount of fibrinolysin activity rules out the possibility that the commercial thrombin used could supply significant amounts of fibrinolysin. 
